Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)

NCT02401503 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leucemia

Interventions

DRUG: Bendamustine
DRUG: GA101
DRUG: ABT-199

Sponsor

German CLL Study Group

Collaborators

[object Object]
[object Object]